검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Methylprednisolone (Methylprednisolone) Genentech, Inc.·Ann Arbor Stage IIB Hodgkin Lympho… ORR 88%·t½ 2.7 h |
|---|---|
Overview Program | Methylprednisolone |
Overview Company | Genentech, Inc. |
Overview Modality | ADC |
Overview Target | Ann Arbor Stage IIB Hodgkin Lymphoma |
Overview Indication | Rheumatoid Arthritis |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the |
MoA Biomarker | biomarker analyses and regional guidelines, particularly from East Asia, were reviewed to examine the indicat |
PK/PD Half-life | 2.7 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Unknown |
Clinical Primary efficacy | ORR 88% |
Clinical ORR | 88% |
Clinical Result source | ClinicalTrials.gov NCT00057811 |
Clinical Data Tier / Score | A · 68 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Methylprednisolone (Methylprednisolone) Genentech, Inc.·Ann Arbor Stage IIB Hodgkin Lympho… ORR 88%·t½ 2.7 h |
|---|---|
Overview Program | Methylprednisolone |
Overview Company | Genentech, Inc. |
Overview Modality | ADC |
Overview Target | Ann Arbor Stage IIB Hodgkin Lymphoma |
Overview Indication | Rheumatoid Arthritis |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the |
MoA Biomarker | biomarker analyses and regional guidelines, particularly from East Asia, were reviewed to examine the indicat |
PK/PD Half-life | 2.7 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Unknown |
Clinical Primary efficacy | ORR 88% |
Clinical ORR | 88% |
Clinical Result source | ClinicalTrials.gov NCT00057811 |
Clinical Data Tier / Score | A · 68 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) |
추천 비교
추천 비교